In this free webinar, learn about setting up and managing
multiplex immunofluorescence (mIF) platforms for companion
diagnostics (CDx) and clinical programs. Attendees will discover
key technical, regulatory and commercial considerations when
defining a CDx strategy for mIF. The featured speakers will also
discuss key strategies for working with pharma companies on CDx
partnerships and developing pre-market approvals (PMAs).
TORONTO, May 24, 2024
/PRNewswire-PRWeb/ -- This webinar aims to provide insights into
immunofluorescence-based biomarker analysis with key considerations
for developing a companion diagnostic (CDx). These include avoiding
common pitfalls associated with multiplex immunofluorescence (mIF)
and multispectral imaging, and successfully harnessing its full
potential in the clinical setting.
These techniques have become indispensable
for gathering critical data from clinical programs.
Recently, there have been many advancements in examining
biomarker expression and heterogeneity within the tumor
microenvironment using high-throughput technologies. However,
current clinical tests for biomarkers often fall short in providing
sufficient information to effectively predict treatment
response.
Multiplex fluorescence immunohistochemistry and image data
analysis have helped uncover meaningful spatial relationships
between specific biomarkers, offering valuable insights into
patient responses to immune checkpoint inhibitors, antibody-drug
conjugates (ADCs) and DNA damage response (DDR) targeted therapies.
These techniques have become indispensable for gathering critical
data from clinical programs.
As mIF techniques mature as an analytical platform, it is
important to understand the technology's fundamentals and its
application in assessing the response for both mono- and
combination therapies.
This webinar will also cover the critical aspects of working
with pharma companies on CDx partnerships and the process of
developing pre-market approvals (PMAs) for these diagnostics.
Register for this webinar to explore the latest advancements in
multiplex immunofluorescence and CDx partnerships and how these
technologies are transforming clinical trials and improving patient
outcomes in immuno-oncology.
Join experts from Akoya Biosciences, Pascal Bamford, Senior Vice President, R&D
and Laboratory Operations; and Mark
Landers, Vice President, Precision Medicine, for the live
webinar on Monday, June 10, 2024, at
2pm EDT (11am
PDT).
For more information, or to register for this event, visit
Advancing Spatial Biology to the Clinic: The Power of Multiplex
Immunofluorescence-based Biomarkers for Companion Diagnostics.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading
provider of educational webinars and digital content to the global
life science, food, healthcare and medical device communities.
Every year, thousands of industry practitioners (from
pharmaceutical, biotechnology, food, healthcare and medical device
companies, private & academic research institutions, healthcare
centers, etc.) turn to Xtalks for access to quality content. Xtalks
helps professionals stay current with industry developments,
regulations and jobs. Xtalks webinars also provide perspectives on
key issues from top industry thought leaders and service
providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit
https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1
(416) 977-6555 x371, skumar@xtalks.com, https://xtalks.com
View original content to download
multimedia:https://www.prweb.com/releases/advancing-spatial-biology-to-the-clinic-the-power-of-multiplex-immunofluorescence-based-biomarkers-for-companion-diagnostics-upcoming-webinar-hosted-by-xtalks-302154803.html
SOURCE Xtalks